CA3157892A1 - Small molecule furin inhibitors for treating infectious diseases - Google Patents

Small molecule furin inhibitors for treating infectious diseases Download PDF

Info

Publication number
CA3157892A1
CA3157892A1 CA3157892A CA3157892A CA3157892A1 CA 3157892 A1 CA3157892 A1 CA 3157892A1 CA 3157892 A CA3157892 A CA 3157892A CA 3157892 A CA3157892 A CA 3157892A CA 3157892 A1 CA3157892 A1 CA 3157892A1
Authority
CA
Canada
Prior art keywords
pyridin
methyl
piperidin
yfloxy
piperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3157892A
Other languages
English (en)
French (fr)
Inventor
Keith Wilcoxen
Claudine MAPA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BP Asset V Inc
Original Assignee
BP Asset V Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BP Asset V Inc filed Critical BP Asset V Inc
Publication of CA3157892A1 publication Critical patent/CA3157892A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3157892A 2019-11-12 2020-11-12 Small molecule furin inhibitors for treating infectious diseases Pending CA3157892A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962934407P 2019-11-12 2019-11-12
US62/934,407 2019-11-12
PCT/US2020/060108 WO2021097009A1 (en) 2019-11-12 2020-11-12 Small molecule furin inhibitors for treating infectious diseases

Publications (1)

Publication Number Publication Date
CA3157892A1 true CA3157892A1 (en) 2021-05-20

Family

ID=73793799

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3157892A Pending CA3157892A1 (en) 2019-11-12 2020-11-12 Small molecule furin inhibitors for treating infectious diseases

Country Status (8)

Country Link
US (1) US20230011571A1 (https=)
EP (1) EP4058021A1 (https=)
JP (1) JP2023503852A (https=)
KR (1) KR20220104744A (https=)
CN (1) CN114929220A (https=)
AU (1) AU2020382819A1 (https=)
CA (1) CA3157892A1 (https=)
WO (1) WO2021097009A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020022961A2 (pt) 2018-05-11 2021-02-17 Glaxosmithkline Intellectual Property Development Limited inibidores de furina
DE102023126563A1 (de) * 2023-09-28 2025-04-03 Philipps-Universität Marburg, Körperschaft des öffentlichen Rechts Hemmstoffe der Proproteinkonvertase Furin, Verfahren zu deren Herstellung und Verwendung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037346A1 (en) * 2001-10-31 2003-05-08 Cell Therapeutics, Inc. 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
EP2478766A3 (en) 2007-05-09 2012-08-15 Burnham Institute for Medical Research Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens
US20150051138A1 (en) * 2012-03-16 2015-02-19 Sanford-Burnham Medical Research Institute Inhibitors of furin and other pro-protein convertases
US10150742B2 (en) * 2013-03-15 2018-12-11 President And Fellows Of Harvard College Substituted heterocyclic compounds for treating or preventing viral infections
CN107441094B (zh) * 2017-08-08 2020-05-22 南方医科大学 尼罗替尼作为治疗登革病毒感染的药物及其制药用途
BR112020022961A2 (pt) * 2018-05-11 2021-02-17 Glaxosmithkline Intellectual Property Development Limited inibidores de furina

Also Published As

Publication number Publication date
US20230011571A1 (en) 2023-01-12
KR20220104744A (ko) 2022-07-26
EP4058021A1 (en) 2022-09-21
JP2023503852A (ja) 2023-02-01
WO2021097009A1 (en) 2021-05-20
CN114929220A (zh) 2022-08-19
AU2020382819A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
ES2823049T3 (es) Derivados de carbamato de 1,1,1-trifluoro-3-hidroxipropan-2-ilo y derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ilo como inhibidores de MAGL
CN109641898B (zh) 用于治疗神经和神经退行性疾病的5,7-二氢-吡咯并-吡啶衍生物
JP7035055B2 (ja) Ｎ－（ピリジン－２－イル）ピリジン－スルホンアミド誘導体および疾患の処置におけるそれらの使用
US11773078B2 (en) Furin inhibitors
ES2536433T3 (es) Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
CA3050625C (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
TWI801540B (zh) 哌嗪氮雜螺衍生物
US10604502B2 (en) Substituted 5-cyanoindole compounds and uses thereof
CA3050853A1 (en) Heterocyclic spiro compounds as magl inhibitors
US11319321B2 (en) [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors
KR20160142402A (ko) 도파민 d1 리간드로서 헤테로방향족 화합물 및 이의 용도
WO2025014877A2 (en) Triazolo wrn inhibitors
US20200231563A1 (en) Novel heterocyclic compounds as modulators of mglur7
JP2024545235A (ja) 複素芳香族化合物、その製造方法及び使用
CA3157892A1 (en) Small molecule furin inhibitors for treating infectious diseases
JP2019501930A (ja) ６，７，８，９−テトラヒドロ−５Ｈ−ピリド［２，３−ｄ］アゼピンドーパミンＤ３リガンド
CA3173921A1 (en) Furin inhibitors for treating coronavirus infections
JP2025061117A (ja) Ｐｄｅ１０化合物のプロドラッグ
WO2021097002A1 (en) Use of pyridyloxypyrimidines for treating infectious diseases
WO2021097008A1 (en) Use of pyridyloxypyridines for treating infectious diseases
RU2799824C2 (ru) Ингибиторы фурина
WO2025126115A1 (en) Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligands and methods of use
TW202410897A (zh) 聯芳醚脲化合物
HK40044050A (en) Piperazine azaspiro derivaves
TW202540096A (zh) 靶向降解雄激素受體的雙功能嵌合體的雜環化合物及其用途

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241106

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241106

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241108

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241108

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241108

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241218

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241218

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250424

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251124

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260107